Autoimmune disease

Penn Highlands Healthcare Urges the Community: Help Save Lives. Become an Organ Donor

Retrieved on:

목요일, 4월 11, 2024

She cannot travel far from her dialysis provider as she awaits a donor kidney.

Key Points:

She cannot travel far from her dialysis provider as she awaits a donor kidney.
Eight lives can be saved by one organ donor; and, one tissue donor can heal 75 lives.
You can help people like Lisa who are waiting for an organ, eye or tissue donation by becoming a donor.
You can also become a donor when you renew your driver’s license in person, or online at dmv.pa.gov .

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Retrieved on:

목요일, 4월 11, 2024

PHILADELPHIA, April 11, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications. CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned clinical trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024. Century plans to pursue additional autoimmune disease indication regulatory filings in 2024. Century’s increased research and development activities in autoimmune diseases are further supported by a $60 million private placement of its common stock to certain institutional investors. Concurrently, Century announced pipeline and platform enhancements through the acquisition of Clade Therapeutics, Inc. (“Clade”), a privately-held biotech company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, with a focus on iPSC-derived αβ T cells. The acquisition brings additional iPSC-focused pipeline programs and technology to Century spanning across cancer and autoimmune diseases.

Key Points:

Century plans to pursue additional autoimmune disease indication regulatory filings in 2024.
Century’s increased research and development activities in autoimmune diseases are further supported by a $60 million private placement of its common stock to certain institutional investors.
The acquisition brings additional iPSC-focused pipeline programs and technology to Century spanning across cancer and autoimmune diseases.
With support from a distinguished group of investors, coupled with the acquisition of Clade, we are poised for continued success,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century.

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Retrieved on:

목요일, 4월 11, 2024

SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.

Key Points:

In support of the acquisition, Eliem has entered into a securities purchase agreement for a $120 million private placement of common stock with a syndicate of new and existing institutional life science investors including RA Capital Management, Deep Track Capital, Boxer Capital, Janus Henderson Investors, Pontifax and Samsara Biocapital.
The private placement is expected to close concurrently with the closing of the acquisition.
Immediately following the closing of the acquisition and the private placement, the total cash and cash equivalents of the combined company are expected to be approximately $210 million.
The acquisition and private placement are expected to close in the middle of 2024, subject to approval by Eliem’s stockholders and other customary closing conditions.

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

Retrieved on:

수요일, 4월 17, 2024

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.

Key Points:

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.
To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease.
Artiva is collaborating with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support the evaluation of AlloNK for LN.
The Network, overseen by Lupus Therapeutics, is comprised of leading research centers throughout North America with the purpose of accelerating and optimizing lupus clinical trials.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Retrieved on:

수요일, 4월 10, 2024

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

Key Points:

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Retrieved on:

수요일, 4월 10, 2024

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

Key Points:

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

Replicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on:

월요일, 4월 22, 2024

RNA, Ultra, Cell, Immunization, Autoimmune disease, Gene, Society, Infection, Interim, Annual general meeting, SAN, Vaccine

SAN DIEGO, April 22, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced acceptance of two oral presentations at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11 in Baltimore, Maryland.

Key Points:

SAN DIEGO, April 22, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced acceptance of two oral presentations at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11 in Baltimore, Maryland.
Summary: Ultra-low doses of optimized srRNA vectors achieved immunization with protective antibody titers with minimal reactogenicity in a preclinical influenza model.
This broadened therapeutic window presents the opportunity to use these vectors for many clinical applications.
Summary: RBI-4000, an srRNA vector encoding the rabies glycoprotein encapsulated in a lipid nanoparticle, is the first clinical demonstration of next-generation srRNA technology.

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on:

화요일, 4월 9, 2024

Patient, ICB, Neoplasm, Cancer, Ubiquitin, Biology, AACR, Phenotype, Aberrant, MAVS, Autoimmune disease, PD-1, Pharmaceutical industry

AUSTIN, TX and DURHAM, NC, April 09, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy. These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.

Key Points:

These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
Our efforts in helping to define the underlying biology of acquired resistance were recently revealed with a publication in Cancer Cell,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
TRIM7 also contributes to PD-1 acquired resistance through ubiquitination and degradation of STING and MAVS.
A copy of the AACR presentation will be available on the Investors section of the Company’s website shortly after the event.

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on:

화요일, 4월 9, 2024

TME, Development, Biotechnology, Cell, Teff, SAN, Tumor microenvironment, Cancer, AACR, Neoplasm, Wigginton, Huangshan, Autoimmune disease, PD-1, Vaccine

Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate.

Key Points:

Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate.
Antibody-cytokine conjugates leverage orthogonal mechanisms of action (MoA) in one molecule to induce potent antitumor immune responses.
“BPT567 is designed to coordinately engage antigen-experienced Teff cells that are known to co-express both PD-1 and the IL-18 receptor.
It is anticipated that this profile could ultimately contribute to an improved risk-benefit profile for BPT567 in the clinical setting”.

Allogene Therapeutics Announces Q2 Investor Conference Participation

Retrieved on:

화요일, 4월 9, 2024

SAN, Kite Pharma, News, Therapy, Cancer, Autoimmune disease

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024.
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section.
Following a live webcast, a replay will be available on the Company's website for approximately 30 days.